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ABSTRACT 
Objective. Unpredictable pharmacokinetics of antibiotics in patients with life-threatening bacterial 
infections is associated with drug under- or overdosing. Therapeutic drug monitoring (TDM) may 
guide dosing adjustment aimed at maximizing antibacterial efficacy and minimizing toxicity. Rapid 
and accurate analytical methods are key for real-time TDM. Our objective was to develop a robust 
high -performance liquid chromatography-tandem mass spectrometry method (HPLC-MS/MS) for 
multiplex quantification of plasma concentrations of 12 antibiotics: imipenem/cilastatin, 
meropenem, ertapenem, cefepime, ceftazidime, ceftriaxone, piperacillin/tazobactam, amoxicillin, 
flucloxacillin, rifampicin, daptomycin. 
Methods. A single extraction procedure consisting in methanol plasma protein precipitation and 
H2O dilution was used for all analytes. After chromatographic separation on an Acquity UPLC HSS-
T3 2.1 x 50 mm, 1.8 µm (Waters®) column, quantification was performed by electro-spray 
ionisation-triple quadrupole mass spectrometry with selected reaction monitoring detection. 
Antibiotics were divided in two pools of calibration according to the frequency of analyses requests 
in the hospital routine antibiotic TDM program. Stable isotopically-labelled analogues were used as 
internal standards. A single analytical run lasted less than 9 minutes. 
Results The method was validated based on FDA recommendations, including assessment of 
extraction yield (96-113.8%), matrix effects, and analytical recovery (86.3-99.6%). The method was 
sensitive (lower limits of quantification 0.02-0.5 µg/mL), accurate (intra/inter-assay bias -11.3 to 
+12.7%) and precise (intra/inter-assay CVs 2.1-11.5%) over the clinically relevant plasma 
concentration ranges (upper limits of quantification 20-160 µg/mL). The application of the TDM 
assay was illustrated with clinical cases that highlight the impact on patients’ management of an 
analytical assay providing information with short turn-around time on antibiotic plasma 
concentration.
Conclusion This simple, robust high-throughput multiplex HPLC-MS/MS assay for simultaneous 
quantification of plasma concentrations of 12 daily used antibiotics is optimally suited for clinically 
efficient real-time TDM. 
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1. INTRODUCTION
The development of new antimicrobial agents does not keep the pace with rising bacterial 
resistance. Maximizing the efficacy and safety of the present antibacterial armamentarium is crucial 
for the management of severe bacterial infections. Unpredictable antibiotic distribution and 
elimination in critically ill patients may result in extremely variable antibiotic plasma concentrations 
despite adherence to the recommended dosing regimens [1]. The resulting drug under- or 
overdosing is associated with a risk of treatment failure or toxicity, respectively. Increase of 
antibiotic dosing following documentation of insufficient plasma concentrations, i.e. trough 
concentrations lower than the in vitro minimal inhibitory drug concentration (MIC) for the causative 
microbe, may improve response of life-threatening infections [2-5] and avoid selection of bacterial 
resistance. This scenario is frequently observed in ICU patients with augmented renal clearance 
(e.g. hyperfiltration)[6]. Patients with impaired or rapidly changing renal elimination are at risk for 
antibiotic accumulation. Dose decrease or therapy interruption may be crucial for prevention or 
management of drug-related neurotoxicity of beta-lactams (encephalopathy with coma, 
myoclonias, and seizures) [7, 8]. We found a 50% probability of toxic encephalopathy at trough 
cefepime plasma concentrations above 22 g/mL in febrile neutropenic patients with mild 
impairment of renal function[9].
Therapeutic drug monitoring (TDM)-guided dosing adjustment aims at optimizing antibiotic therapy 
according to the individual clinical condition and in vitro susceptibility of the causative pathogen 
[10-13]. A key of clinically efficient TDM is measurement of plasma antibiotic concentrations with 
short turn-around time. Analytical techniques for quantification of multiple antibiotics using a unique 
extraction procedure, simultaneous calibrations and short turn-around analytical time may best 
fulfill these requirements. The method for multi-compound quantification of beta-lactams by Verdier 
et al.[14] used a chromatographic gradient over 22 minutes with ultraviolet detection. Tandem mass 
spectrometry (MS) detection qualifies for rapid, specific and sensitive quantification in plasma of 
structurally unrelated antimicrobial agents in a single analytical run. MS applications were 
published for the analysis of multiple beta-lactams [15-19] and/or other antimicrobials [20-22]. 
Quantification of antibiotic plasma concentrations may be perturbed by endogenous and 
exogenous compounds from very complex, highly variable plasma matrices influenced by renal 
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and/or hepatic dysfunction and simultaneous drug treatments. In their landmark ultra-performance 
liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) assays, Carlier et al.[23], Colin 
et al.[24], and Zander et al.[25] used isotope-labelled internal standards (I.S.) for correcting the 
potential interferences of plasma matrix variability. Subsequently, MS methods for antimicrobial 
agents included isotope-labelled I.S for most [26-31] or some [32-34] antibiotics. 
Our objective was to develop a robust analytical HPLC-MS/MS method for the quantification of the 
plasma concentrations of 12 daily used antibiotics, covering the entire clinically relevant ranges of 
concentrations. They were classified in two antibiotic pools i) constituted on the basis of the 
frequency of clinical requests in the hospital routine antibiotic TDM program, and ii) with respect to 
the maximum number of antibiotics that can be added into plasma calibration samples without drug 
solubility issues at the upper limits of clinically relevant concentrations. Simple unique extraction 
method, rapid turn-around time and use of stable isotope-labelled antibiotics analogues as internal 
standards aimed at providing an accurate, precise and rapid quantification of plasma 
concentrations for TDM-based drug dosing adjustment in patients with severe bacterial infections. 
Page 6 of 31  
2. MATERIAL and METHODS
2.1. Chemicals, reagents and plasma
All chemicals were of analytical grade. For simplification, the 13 analytes will be designated as 
antibiotics throughout the text, even though cilastatin is a renal dehydropeptidase II inhibitor co-
administered with imipenem to inhibit its enzymatic degradation in the kidney.
Piperacillin, tazobactam and cefazolin were purchased from Sigma-Aldrich Chemie GmbH 
(Buchs SG, Switzerland). The stable isotope-labelled internal standards (I.S.) cefepime-13CD3, 
ceftazidime-D6, ceftriaxone-13CD3, ertapenem-D4, flucloxacillin-13C415N, imipenem-D4, 
piperacillin-D5, were obtained from Alsachim (Strasbourg, France). Amoxicillin, ceftazidime, 
ceftriaxone, rifampicin and the I.S. amoxicillin-D4, daptomycin-D5 (major), meropenem-D6 and 
rifampicin-D8 were purchased from Toronto Research Chemicals Inc. (North York, ON, Canada). 
The pharmaceutical formulations of imipenem and cilastatin (Tienam® I.V., Merck, Zug, 
Switzerland), cefepime (Orpha Swiss, Küsnacht, Switzerland), meropenem (Meronem®, Astra 
Zeneca, Zug, Switzerland), daptomycin (Cubicin®, Novartis, Basel, Switzerland), ertapenem 
(Invanz®, Merck, Zug, Switzerland), flucloxacillin (Floxapen®, Actavis, Regensdorf, Switzerland) 
were used for the preparation of stock solutions, calibration samples and quality control samples 
(QCs). The procedures for the preparation of stock solutions, calibration samples, QCs, and I.S. 
solutions are reported in Table S1, Panel A and B. Chromatography was performed using 
Lichrosolv® HPLC-grade acetonitrile (MeCN) (Merck, Darmstadt, Germany). Ultrapure water was 
obtained using a Milli-Q® UF-Plus apparatus (Millipore Corp., Burlington, MA, USA). Ammonium 
formate (Fluka, Buchs SG, Switzerland) and formic acid (98-100%) (Merck, Darmstadt, 
Germany) were used for the solvents of the mobile phase in the gradient elution program. 
Blank plasma used for the assessment of matrix effect and for the preparation of calibration 
samples and QCs was obtained according to institutional ethical standard from citrated blood 
from patients with polycythemia vera, who underwent regular phlebotomy at the Center of 
Transfusion Medicine, Lausanne University Hospital, Lausanne, Switzerland. The blood was 
centrifuged on a centrifuge Hettich® Rotanta 4600RF (2113g (3000 rpm), 10 min, +4 °C). 
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2.2. LC-MS/MS conditions
The liquid chromatography system consisted of Rheos Allegro quaternary pumps, equipped with 
an online degasser and a HTS PAL autosampler (CTC Analytics AG, Zwingen, Switzerland) 
controlled by Janeiro-CNS 1.1 software (Flux Instruments, AG, Thermo Fisher Scientific, Waltham, 
MA, USA). Separations were done on a column Acquity UPLC HSS T3 2.1 x 50 mm, 1.8 m 
(Waters®, Milford, MA, USA). The chromatographic system was coupled to a triple stage 
quadrupole (TSQ) Quantum Ultra mass spectrometer (MS) from Thermo Fisher Scientific, 
equipped with an electrospray ionization (ESI) (Ion Max Source Probe) interface and operated with 
Xcalibur 2.0.7 software (Thermo Fisher Scientific, Waltham, MA, USA).
The mobile phase was composed of 10 mM ammonium formate in ultrapure water + 0.4% formic 
acid (FA) (solvent A) and acetonitrile (solvent B). The mobile phase was delivered using an initial 
gradient elution followed by an equilibration step of the column to the initial solvent composition 
according to the sequences reported in Table S2. The temperature-controlled autosampler was 
maintained at +4°C.
The HPLC-MS/MS conditions were as follows: electrospray ionization (ESI) in positive mode; spray 
voltage 3800 V; vaporizer temperature 40°C; sheath gas and auxiliary gas (both nitrogen) pressure 
60 and 10 arbitrary units, respectively; capillary temperature 350°C; collision energy (CE) from 5 
eV to 53 eV; tube lens range voltage 57-104 V. The Q2 collision gas (argon) pressure was 1.5 
mTorr (0.199 Pa). Mass spectra (MS) were acquired using the selected reaction monitoring (SRM) 
detection in the positive ionization mode. The selected m/z transitions and the collision energy for 
each analyte and I.S. are reported in Table 1.
The optimal instrument parameters and MS/MS transitions were determined by direct infusion of 
each compound solution separately into the MS/MS detector at a concentration from 1 to 10 g/mL 
in a 50:50 mixture of MeOH and solution A, depending on their sensitivity. 
The optimal instrument parameters for MS/MS analyses are as follows: 
The first (Q1) and third (Q3) quadrupoles were set at 1 amu mass resolution (Full-Width Half-
Maximum = 1.8-2.0 Da). Scan time and scan width were 0.02 s and 0.5 amu, respectively. Each 
chromatographic peak was the result of at least 20 scans. MS acquisitions were done in centroïd 
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mode.  In Pool 1 (see antibiotic list in Table S1, Panel A), three distinct segments of data acquisition 
were programmed in the positive mode: 0 - 2.4 min, 2.4 - 2.85 min, and 2.85 - 6.0 min. For Pool 2 
(see antibiotic list in Table S1, Panel A), the segments were as follows: 0 - 2.3 min, 2.3 - 3.3 min, 
and 3.3 - 6.0 min. Chromatographic data acquisition, peak integration and quantification were 
performed using the QUAL and QUAN browser of the Xcalibur software package (version 2.0.7, 
ThermoQuest, Thermo Fisher Scientific Inc, Waltham, MA, USA).
2.3. Calibration standard, quality control (QCs) and internal standard (I.S.) solutions 
for calibrations curves
The antibiotics imipenem/cilastatin, meropenem, ertapenem, cefepime, piperacillin/tazobactam, 
flucloxacllin, ceftazidime, ceftriaxone, amoxicillin, daptomycin and rifampicin, have been divided in 
two pools of calibration (Pool 1 and 2, respectively) according to the frequency of analyses requests 
in the hospital routine antibiotic TDM program. The preparation of two separate pools was also 
necessary because of solubility issues with multiple compounds spiked in plasma at their highest 
calibration levels (i.e. up to 100 µg/mL, 160 µg/mL for piperacillin). The preparation of calibration 
and QCs samples and of I.S. solutions used for calibration curves is reported in Table S1, Panel A 
and B.
2.4. Plasma extraction procedure 
Plasma (clinical, calibration and control) samples and working solutions were kept on ice at +4°C 
during the entire processing. In a 1.5ml Eppendorf plastic vial placed on ice, a 100l aliquot of 
plasma was mixed with 50l of I.S. working solution (containing each I.S., i.e. for Pool 1 imipenem-
D4, meropenem-D6, cefepime-13CD3, and piperacillin-D5 at 9g/mL, and cefazoline at 18g/mL and 
for Pool 2 amoxicilin-D4, ertapenem-D4, flucloxacillin-13C415N, daptomycin-D5 at 90g/mL, 
ceftazidime-D6 at 9g/mL, ceftriaxone-13CD3 at 2g/mL and rifampicin-D8 at 1g/mL; Table S1, 
Panel B) and 300l of ice cold MeOH, vortexed for 5 sec. The mixture was centrifuged at +4°C for 
10 minutes at 20’000 g (14’000 rpm) on a Mikro 200R benchtop centrifuge (Hettich GmbH, 
Tuttlingen, Germany). A 80l aliquot of the supernatant was diluted without delay with 480l of 
ultrapure H2O, into 2mL glass HPLC vials, tightly closed with crimp seals and vortexed for 10 sec. 
A volume of 20l was injected into UPLC-MS/MS for analysis.
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2.5. Analytical method validation
The method validation procedure was based on : i) 2018 on-line recommendations of the Food and 
Drugs Administration (FDA)[35], ii) recommendations of the Conference Report of the Washington 
Conference on “Analytical Methods Validation: Bioavailability, Bioequivalence and Pharmacokinetic 
studies”[36], iii) Arlington Workshop “Bioanalytical Methods Validation - A revisit with a Decade of 
Progress”[37], iv) recommendations on methods validation from Matuzewski et al. [38, 39].
2.6. Accuracy and precision
Four concentrations of quality control samples (QCs) were used to cover the rather large analytical 
range of the calibration curves including the spectrum of antibiotic concentrations expected to be 
measured in clinical samples: low (L), intermediate (I), medium (M), and high (H) (Table S1, Panel 
A). Replicate analyses (n=6) of the four QCs were performed for assessment of intra-assay (within 
a single analytical run) and inter-assay (among different runs) accuracy and precision. The 
accuracy was calculated as the bias, or percentage of deviation, between measured and nominal 
concentrations. The precision was calculated as the coefficient of variation (C.V. %) of the 
measured concentrations.
2.7. Matrix effects, extraction yield and overall recovery
The same methodology was previously applied for the validation of the multiplex LC-MS/MS assay 
developed in our laboratory for antifungal drugs[40]. The matrix effects and their variability were 
examined qualitatively by the simultaneous post-column infusion of the antibiotics and 
corresponding I.S. into the MS/MS detector during the chromatographic analysis of 6 different blank 
plasma extracts. The chromatographic signals of each selected MS/MS transition were examined 
to check for any signal perturbation (drift or shift) of the MS/MS signal at the analytes’ retention 
time. The matrix effects , ME (i.e. ion suppression/enhancement of the MS/MS signal of drugs in 
presence of plasma matrix), the extraction yield and overall recoveries were quantitatively 
assessed based on recommendations by Matuszeski et al. [39] (Supplementary Material).
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2.8. Lowest Limit of quantification 
The lowest limit of quantification (LLOQ) for each drug was the minimal plasma concentration, 
which could be quantified with a  20% deviation of the measured from the nominal concentration, 
in accordance with FDA recommendations. 
2.9. Antibiotics stability over time in plasma and whole blood at different storage 
conditions, method selectivity and anticoagulant’s influence
These studies are described in details in Supplementary Material.
2.10    Clinical blood samples
Clinical samples from patients receiving antibacterial therapy for severe bacterial infections were 
analyzed with the new HPLC-MS/MS method as a quality control in the frame of the hospital routine 
antibiotics TDM program. According to Swiss Law and Institutional rules, ethical approval is not 
required for a retrospective case report involving anonymised clinical data (see the Federal Act on 
Research involving Human Beings [41]. Blood samples (2.7 ml) were collected in Monovettes® 
(Sarstedt, Nümbrecht, Germany), containing initially citrate, thereafter EDTA (which should be 
preferred, see below) as anticoagulant. Blood samples were centrifuged within 1 hour at 1850g 
(3000rpm) (Beckmann Centrifuge, Model J6B, Nyon, Switzerland), or at 2113g (3000rpm) on a 
Rotanta® 4600RF centrifuge (Hettich GmbH, Tuttlingen, Germany), for 10 min at +4°C. The plasma 
was separated and transferred into 5ml polypropylene test tubes, and directly analyzed (turn-
around time within 6h), or frozen at -80°C and analyzed within 48h (e.g. external shipments from 
other hospitals). 
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3. RESULTS 
3.1. Chromatograms
The multiplex HPLC-MS/MS method with an analytical run lasting less than 9 minutes quantified 
the plasma concentrations of 12 antibiotics plus cilastatin. Chromatographic profiles of calibration 
samples containing 25g/ml of antibiotics from Pool 1 and 2 are shown in Figure 1a and Figure 1b, 
using the gradient elution programs described in Table S2. The respective retention times and 
mass spectrometry conditions for antibiotics and their stable isotopically-labelled I.S. are reported 
in Table 1. 
3.2. Internal standard and calibration curve 
Deuterated (D)-, 13C- or 15N- analogues (and combinations thereof) of antibiotics were used as 
Internal Standards (I.S.). The I.S. imipenem-D4 was of critical importance since the polar imipenem 
was eluted early on a reverse phase mode and its signal could be perturbed by endogenous 
hydrophilic components. In addition, imipenem-D4 could correct for the irregular shape of imipenem 
signal due to the equilibrium between imipenem Z and E isomers [42] that may be partially resolved 
under the applied chromatographic conditions (see below). 
Labelled internal standards for cilastatin or tazobactam were not available to us at the time of the 
initial setting-up of the method, but cefazoline was found to be a suitable I.S. (see Table S4) for 
these compounds which formally are not subjected to TDM, but are measured concomitantly for 
informative purposes.
Calibration curves over the clinically relevant concentrations ranges reported in Table S1, Panel A 
were best described by 1/x2 weighted quadratic log-log regression of the peak-area ratios of the 
antibiotic to its I.S. in each standard sample, which were referred to the respective nominal 
concentrations. This model of calibration was used in order to obtain a minimum bias for each 
single calibrator over the entire calibration range (data not shown). The regression coefficients r2 
of all calibration curves were higher than 0.99 with back-calculated concentrations of the calibration 
samples within ±15% (±20% at LLOQ) of the nominal concentrations. 
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3.3. LLOQ, accuracy, and precision 
The lower levels of quantification (LLOQs) corresponded to the lowest levels of calibration reported 
in Table S1, Panel A. For Pool 1 antibiotics, the LLOQs were within 0.05-0.08g/mL. For Pool 2, 
the LLOQs were 0.02g/mL (rifampicin), 0.1g/mL (amoxicillin, flucloxacillin, ceftazidime and 
ertapenem), and 0.5g/mL (ceftriaxone and daptomycin). The accuracy and precision of the LLOQs 
for all antibiotics were within the ±20% limit recommended by the FDA. Accuracy and precision for 
the four QC samples are summarized in Table S3. The intra-assay and inter-assay deviation (bias) 
from the nominal concentrations of QCs ranged -7.1 to +12.7%, and -11.3 to +6.8%, respectively. 
The intra-assay and the inter-assay precision (CV) ranged from 1.4 to 11.5%, and from 2.1 to 
11.3%, respectively. All the measured intra- and inter-assay accuracy and precision parameters 
lied within the ±15% range recommended by the FDA. Our laboratory participates to inter-
laboratory (external) QC proficiency programs for antibiotics [43-45] which confirmed analytical 
accuracies and precisions within the recommended validation ranges (data not shown). 
3.4. Matrix effect and recovery
The matrix effects were analyzed qualitatively by the simultaneous post-column infusion of all 
analytes and I.S. into the MS/MS detector during the chromatographic analysis of blank plasma 
extracts from six different batches of blood donors. As illustrated in Figure S1 (Supplementary 
material) signals at the m/z transition showed a similar pattern for all traces: no significant drifts or 
shifts of selected transition signals (overlapping traces in offset) were apparent at the retention time 
of each antibiotic, except for piperacillin in Pool 1, for which a significant drop was observed, that 
was reproduced in quantitative assessment (Table S4), albeit compensated by its I.S. (see below).
The inter-subject variations in matrix effects have been studied quantitatively in Table S4. Using 
the protein precipitation with MeOH and supernatant dilution 1+6 in purified H2O, the variability in 
matrix effect (ME) of the 13 analytes in 6 different plasma matrices was below 11.8% and 12.8%, 
for Pool 1 and Pool 2, respectively (column ME%, Table S4). 
A comprehensive assessment of the ME, extraction recovery, and overall method recovery for all 
antibiotics is reported in Table S4. The mean ME was around 100% for imipenem, meropenem, 
cefepime, tazobactam, cilastatin, amoxicillin, ceftazidime, ertapenem and rifampicin. ME values for 
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piperacillin, daptomycin and flucloxacillin were 82.5%, 88.7% and 87.3%, respectively, indicating a 
weak (around -15%) negative matrix effect, whereas the ME was 165.2% for ceftriaxone, reflecting 
an important positive matrix effect. However, the B2/A2 ratio (i.e. ME normalized with stable 
isotope-labelled I.S. signals) for piperacillin, daptomycin, flucloxacillin, and ceftriaxone were 103%, 
93.7%, 98.7%, and 101.7%, respectively, demonstrating that the use of a labelled I.S. successfully 
corrected the ME (either negative or positive) observed for these four antibiotics. The mean 
extraction yield ranged between 96% (imipenem) to 113.8% (daptomycin). The mean overall 
process efficiencies (PE) were comprised between 82.8% (piperacillin) and 106.3% (cilastatin), 
with the exception of a PE at 165.2% for ceftriaxone due to a positive ME, fully corrected by the 
use of the I.S. ceftriaxone-13CD4. For all antibiotics the variability of the overall PE was low (< 15%) 
(Table S4). 
3.5. Carry-over (memory) effect 
No carry-over was observed in blank samples analyzed immediately after two injections (i.e. an 
extreme case scenario) of the highest calibration levels, except for ceftriaxone, daptomycin, 
flucloxacillin, and rifampicin, whereby the first following blank sample showed a signal 
corresponding to a concentration of 0.34, 0.39, 0.12 and 0.04 µg/ml, respectively, unlikely to 
influence to a clinically significant extent the analytical results. However, it is advised to program 
the analysis of one blank sample (MeOH/H2O 50:50) immediately after the highest calibration level 
to eliminate a potential memory effect for these antibiotics.
3.6. Stability studies 
The quantification over time of QCs of antibiotics from Pool 1 and Pool 2, in plasma and whole 
blood at RT and +4°C, is reported in Table 2, left and right column, respectively. 
In plasma at RT, the measured concentrations were within 85-115% of the nominal concentrations 
up to 4h for imipenem, up to 8h for cefepime, meropenem, and piperacillin/tazobactam, up to 24h 
for amoxicilin, ceftazidime, and ertapenem, and up to 48h for ceftriaxone, flucloxacillin, 
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daptomycin, rifampicin, and cilastatin. All antibiotics remained stable up to 48h in plasma stored 
at +4 °C, except imipenem that was stable (-14.3%) up to 24h. 
In citrated whole blood samples, all antibiotics, with exception of meropenem and imipenem, were 
stable up to 24h and 48h, when stored at RT and +4°C, respectively. Imipenem and meropenem 
remained within 85-115% of the initial concentration in whole blood at RT up to 2h and 8h, 
respectively. Storage of whole blood samples at +4° slowed a degradation of imipenem and 
meropenem (-13% and -15% from T0 values after 8 and 24h, respectively). 
The concentrations of antibiotics/cilastatin in plasma after three freeze-thaw cycles were within 
85-115% of those measured at T0, except for the L level of imipenem after the third cycle (-17%, 
data not shown).
Quantification of QCs of antibiotics at -80°C was within 85-115% of the values at T0 up to 2 months 
and 3-4 months, for Pool 1 and Pool 2, respectively (data not shown).
3.7. Influence of anticoagulants 
The method has been validated using citrated plasma for the preparation of matrix-matched 
calibration samples and QCs. The validation was completed by analyzing four series of the four 
(L, I, M, H) QCs prepared in serum, citrated, heparinized or EDTA plasma, using calibration 
curves in citrated plasma. In heparinized plasma samples, the measured imipenem, tazobactam, 
and meropenem concentrations exceeded 115% of the nominal values, especially for the L QCs, 
indicating that, in our assay, heparin is not an appropriate anticoagulant for blood sampling. For 
all other antibiotics, the concentration deviations using serum, heparinized or EDTA plasma were 
comprised within 85-115% of the nominal concentrations. When blood is collected in tubes 
containing 10% volume of citrate solution, such dilution implies a correction of the measured 
plasma concentration by a factor of 1.1, which is correct if the blood collection tube is completely 
filled. 
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3.8. Clinical application of the multiplex UPLC-MS/MS method for TDM-guided patients’ 
management
The application of the multiplex UPLC-MS/MS method is illustrated with clinical cases from the 
hospital routine antibiotic TDM program (Figure 2, Panel A to I) highlighting the impact on patients’ 
management of an assay that provides real-time information on antibiotic plasma concentrations. 
Figure 2, Panel A shows the chromatographic profile of plasma collected at steady state in a 3-
year old child (15 kg) receiving 350mg imipenem + cilastatin (Tienam®) i.v. over 60 min every 6h 
for suspected knee osteomyelitis. The trough plasma concentration of imipenem was 0.2g/mL 
(cilastatin < 0.1g/mL) (Figure 2, Panel A), which was below the target of 1g/mL recommended 
for appropriate antibacterial activity when the MIC of the causative pathogen is unknown [3]. This 
prompted dosing increase to 500mg administered as a 2h-infusion every 6h. After 24 hours, the 
trough level was 1.6g/mL (cilastatin 0.3g/mL) (Figure 2, Panel B). The signal peak for imipenem 
in Figure 2, Panel A and Panel B was broadened (such as in Figure 1A) due to the presence of E/Z 
isomers, which were not separated with the analytical conditions used for TDM (see below Figure 
3A). 
Figure 2, Panel C illustrates the chromatographic profile of plasma collected in a 85-year old patient 
(72kg, 166M serum creatinine) treated with cefepime 2g bid for foot osteomyelitis. During 
antibiotic therapy he developed a delirium. TDM showed a cefepime plasma trough concentration 
of 61.5g/ml, while the recommended trough level should not exceed 15g/ml [9]. This result 
suggested a cefepime accumulation due acute renal failure complicated by a toxic encephalopathy. 
The documentation of cefepime overdosing with concurrent neurological signs prompted treatment 
interruption, which resulted in complete clinical resolution within 24h. Cefepime therapy was 
resumed at an adapted dosing of 1g bid. 
Figure 2, Panel D and E represent the chromatographic profiles of plasma from a 33- year old 
patient (72kg, 53M serum creatinine, with a Clcrt 182ml/min calculated according to Cockroft & 
Gault) with small bowel perforation and polymicrobial peritonitis (Enterobacter cloacae, 
Pseudomonas sp., alpha-hemolytic Streptococcus, E. faecium, S. epidermidis, S. haemolyticus). 
He received high-dose meropenem (2g tid) as undetectable imipemen Cmin plasma concentrations 
had been measured during a previous treatment course with 750mg 4 times a day (qid). His 
Page 16 of 31  
creatinine plasma levels decreased to 33M, with a corresponding Clcrt of 287ml/min and a 
meropenem plasma trough concentration of 0.2g/ml (Figure 2, Panel D), reflecting insufficient 
antibiotic exposure. The detection of low meropenem blood concentrations in this patient with renal 
hyperfiltration was followed by dose adjustment to 2g qid as 2-hour infusion resulting in meropenem 
trough concentrations at 3.7g/ml (Figure 2, Panel E). 
Figure 2, Panel F represents the chromatographic profile of plasma from a 81-year old patient 
(75kg, Clcrt 55ml/min calculated according to Cockroft & Gault) treated with daptomycin for 
methicillin-resistant Staphylococcus epidermis post-surgical mediastinitis with bloodstream 
infection. He received daptomycin (Cubicin®) 500mg (6mg/kg) i.v. once daily, in association with 
oral rifampicin 300mg BID. The patient was discharged on parenteral antibiotic therapy and 24 
hours later he complained of myalgias. His creatine kinase (CK) concentration was 2012 U/L 
(normal range: 25-195 U/L), and daptomycin trough plasma concentration was 28.5g/ml (Figure 
2, Panel F) [10g/ml 48 hours and 0.3g/ml 5 days after the last dose, data not shown]. The mean 
Cmin reported for daptomycin at this dosing regimen is 6.7g/ml [46]. These findings reflected a toxic 
rhabdomyolysis due to daptomycin accumulation resulting in drug overdosing. After daptomycin 
interruption, myalgias resolved and CK values normalized. In this patient with mild impairment of 
renal function, TDM documented daptomycin accumulation resulting in muscular toxicity that 
required treatment interruption and switch to an alternative antibiotic therapy.
A 88-year old woman (60kg) with chronic renal failure (150mol/L serum creatinine; eGFR 
27ml/min/1.73 m2) was diagnosed with E. cloacae and P. aeruginosa surgical wound infection after 
peripheral arterial by-pass grafting. She received cefepime 2g bid. Two days after treatment 
initiation she developed aphasia followed 24 hours later by myoclonias, along with deterioration of 
the Glasgow Coma Scale (GCS) score to 12/15. The EEG diagnosed a status epilepticus, treated 
with clonazepam, levetiracetam and valproate. The chromatographic profile of plasma showed a 
cefepime trough concentration of 83.3g/ml, (Figure 2, Panel G), an extremely high level when 
compared to the recommended therapeutic range 2-15g/ml [9]. This cefepime overdosing due to 
chronic renal failure resulted in severe neurotoxicity. Hemodialysis was initiated and cefepime pre-
filter and post-filter concentrations were monitored (Figure 2, Panel H and I): 57.5g/ml and 
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8.3g/ml, respectively, were measured 55min after starting hemodialysis. This allowed decreasing 
the cefepime trough concentration in plasma to 24.1g/ml after the first dialysis, and to 2.5g/ml 
after the second dialysis 24 hours later. The patient fully recovered from the cefepime neurotoxicity 
after 72 hours. Of note, the 7-epimer of cefepime [47] (see below) was detected in all samples 
(plasma, pre- and post-dialysis column) collected from this woman with renal failure (Figure 2, 
Panel G, H, and I). 
3.9. Isomers profiles and metabolites identification studies for imipenem and 
cefepime 
Given the reduced elution time of the analytes with UPLC, it was important to check for 
interferences with drug quantification by beta-lactams isomers. The chromatographic elution 
pattern of isomers was studied for imipenem and cefepime. Imipenem is eluted as a broad peak 
(Figure 1, Panel A) that can resolve into a nearly base-line separation of two peaks existing at a 
7:3 ratio when applying a more prolonged gradient program (0 min to 4min: 98% → 60% Solvent 
A; followed by column re-equilibration to the initial solvent composition (98% Solvent A)) (Figure 
3, Panel A). Imipenem has been shown to exist as a mixture of two rotational Z and E 
formamidinium isomers that are in equilibrium in solution, and that can be separated 
chromatographically (41). Preparative HPLC isolation of one single isomer was reported to give 
an enriched solution of one isomer, which rapidly re-equilibrates to the original 7:3 composition 
within minutes at pH 7 and at RT (41). For imipenem quantification, a base-line separation of Z 
and E isomers was not considered, since under physiological pH and temperature conditions, the 
equilibrium is expected to be dynamic without any influence on imipenem pharmacological 
properties. The use of the stable isotopically-labelled I.S. imipenem-D4 was however essential for 
normalizing the imipenem peak shape feature which is changing over the concentration range, 
and for correction of the matrix effect of polar endogenous compounds possibly co-eluting with 
imipenem. 
In patients receiving cefepime, a second small peak could be observed in some plasma samples 
at the SRM transitions (m/z 481.2→125; 481.2→396.2) selected for cefepime, close after the 
main peak of cefepime eluted at 2.3-2.5 min (Figure 2, Panel G, H, and I). Base-line resolution of 
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cefepime and its isomer was obtained using the following gradient adaptation: 0 min to 4min: 98% 
→ 60% Solvent A, which allows a recording of the mass spectrum of cefepime and its isomer 
(Figure 3, Panel B). The mass spectrum and fragmentation pattern of this metabolite in patients 
was virtually identical to that of standard cefepime spiked into blank plasma. Addition of cefepime 
pure standard to patient’s plasma samples containing both cefepime and its isomer, increases 
uniquely the cefepime signal, indicating that, unlike imipenem, the presence of this additional 
peak is not due to an isomeric equilibrium. We hypothesized that this second peak is related to 
the 7-epimer of cefepime (Figure 3, Panel B) that has been identified in vivo (46), and has been 
reported to correspond to 2.5% of a 1000 mg dose of (radiolabelled) cefepime excreted in urine 
by healthy subjects. In the majority of plasma samples from patients receiving cefepime, the level 
of this metabolite, if present, was very low (Figure 2, Panel C), except in patients with impaired 
renal function (Figures 2, Panel G, H, and I). In these patients, the concentrations of the 
metabolite (calculated using the IS cefepime-13CD3 and cefepime calibration) correspond up to 
40.5% (mean 14.7% (range 3.5-40.5%, n= 50)) of that of cefepime. In the absence of information 
on a potential influence of stereochemistry on cefepime’s antibiotic activity (which should a priori 
be irrelevant, given the intact beta-lactam cycle), the cefepime signal was integrated as a single 
peak for the calculation of the plasma concentration for routine TDM (Figure 2, Panel G, H, and 
I). 
4. DISCUSSION AND CONCLUSION
This new multiplex HPLC-MS/MS method was developed to meet laboratory and clinical 
requirements for an efficient TDM: i) simple workup with a unique procedure of sample extraction 
and processing for 12 antibiotics; ii) excellent extraction yield with MeOH precipitation, iii) high 
sensitivity and specificity (lower LOQs 0.02-0.5g/ml with isotope-labelled antibiotic analogues as 
I.S.); iv) extended analytical range over a factor 200 to 2000 (higher LOQs 20-160g/ml) directly 
covering the entire clinically relevant concentrations spectra; v) multiplex approach with 
establishment of 13 calibration curves for simultaneous quantification of the corresponding 
analytes; vi) short analytical turn-around time (single analytical run lasting less than 9 minutes) 
providing results within 6h and allowing TDM-based dosing adjustments in real-time. 
Page 19 of 31  
The use of stable isotope-labelled (13C, 15N, deuterium) analogues as I.S. for the simultaneously 
quantified antibiotics was a major strength of this new method, when compared with previous 
assays, which simultaneously quantified a smaller number of compounds and/or did not use I.S. 
for all the tested antibiotics [26-34]. Stable I.S. played a key role to circumvent the potential 
influence on antibiotics ionization of highly variable matrices in plasma samples collected from 
patients with impaired renal and/or hepatic function and simultaneously receiving multiple 
medications. The I.S.-guided correction also allows an accurate quantification of antibiotics 
concentrations in matrices other than plasma such as ultrafiltrate fluid from continuous renal 
replacement therapy (CRRT), urine, cerebrospinal fluid, and other biological fluids.
The use of a unique plasma extraction and a single supernatant dilution step providing 
simultaneously the best analytical sensitivity over the entire clinically relevant concentrations 
ranges of all analytes was a major achievement in the optimization of the pre-analytical plasma 
processing. Of note, the more polar antibiotics were found to have a limited solubility in MeOH, and 
therefore the plasma/organic solvent ratio was limited to 1+2 for the plasma proteins precipitation. 
In such conditions, the use of ice cold MeOH added to plasma kept at +4°C was found suitable for 
maximizing the plasma proteins precipitation. Yet, the plasma protein precipitation step with ice 
cold MeOH yielded a plasma supernatant with a relatively high organic content of 67% MeOH, in 
which the more polar antibiotics have a limited solubility. It was therefore important to dilute without 
delay the supernatant with purified H2O to maintain the polar antibiotics in an aqueous medium 
ensuring stability in the auto-sampler at +4°C during the entire analytical sequence. 
The existence of isomers of imipenem [42] and cefepime [47] had not been accounted for or only 
partially investigated [14, 32] in previous analytical developments. The present chromatographic 
studies support the existence of a dynamic equilibrium between the Z/E formamidium rotational 
isomers of imipenem in both calibration and patients’ samples. This chemical characteristic had 
probably no clinical relevance. The presence of the 7-epimer of cefepime had only been observed 
in clinical samples, with especially high proportions in plasma from patients with renal failure. To 
which extent this epimer contributed to the neurotoxic effects of cefepime overdosing remains to 
be determined. 
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Several pre-analytical and clinical requirements had been considered in the present development. 
A plasma volume of 100L was needed for analysis, which was particularly suitable for TDM in 
neonates and infants. If necessary, the LLOQ allowed this volume to be reduced to 50L. The 
definition of clinically relevant calibration ranges was based on concentrations expected according 
to pharmacokinetic studies and in vitro bacterial susceptibility, by prioritizing upper limits of 
quantification over clinically irrelevant sensitivity. 
The conditions for handling of blood samples by nursing personnel and for pre-analytical 
processing and storage in the laboratory had been investigated. For standardizing conditions of 
routine antimicrobial TDM, we recommend that blood is centrifuged within 30 minutes after 
venipuncture and plasma immediately stored at -80°C. For TDM in samples received from other 
hospitals, plasma needs to be sent frozen on dry ice. Method validation has been carried out using 
blank plasma from citrated blood collection. Yet, we have found that EDTA and serum can be used 
instead indifferently, and we recommend for optimal quantification of antibiotic concentrations to 
use EDTA as anticoagulant in TDM blood sampling (no need for correction (f =1.1) for the volume 
of anticoagulant solution contained in the tube and the volume of blood collected, as for citrate). 
Serum is a valid alternative. 
Participation to external quality proficiency programs [43-45] provided the demonstration of the 
reliability and robustness of our analytical method and its compliance with the criteria of quality 
recommended for routine clinical application of TDM [12].
The simultaneous analysis of different compounds with short turn-around time has a substantial 
impact on timing of clinical decisions. Antibiotic dosing adjustment in patients undergoing CRRT 
could be guided by TDM results following online algorithms. We illustrated some clinical situations 
from the hospital routine antibiotic TDM program in which detection of drug over- or underdosing 
associated with toxicity or non-response was key for appropriate patient management.  In patients 
presenting neurological symptoms and signs during cefepime therapy, documentation of plasma 
concentrations above the toxic threshold was crucial for prompt interruption of antibiotic therapy. 
For daptomycin, TDM-guided dose adjustment in patients with renal insufficiency may prevent toxic 
rhabdomyolysis. Real-time information on insufficient plasma concentrations of imipenem and 
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meropenem allows dose adjustment for improving antibiotic exposure, especially in ICU patients 
with renal hyperfiltration who are at high risk for drug underdosing [6]. 
In conclusion, this robust, sensitive and selective multiplex UPLC-MS/MS analytical method 
accurately and precisely quantifies plasma concentrations of 12 daily used antibiotics with high 
throughput, i.e. with a unique plasma extraction step and a 9-minute analytical run. This new assay 
providing analytical results within 6 hours offers an efficient tool for TDM aimed at individualizing 
drug dosing for optimal efficacy and minimal toxicity. These characteristics are of key importance 
for establishing new standards of treatment individualization in patients with life-threatening 
infections. 
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8. FIGURES INDEX AND LEGENDS
Figure 1: Multiplex analysis by UPLC-MS/MS for quantification of the plasma concentrations 
of 12 antibiotics with corresponding internal standards. Chromatographic profile of a 
plasma calibration sample at 25g/ml for Pool 1 (Panel A: imipenem, cilastatin, 
meropenem, cefepime, piperacilline, tazobactam, cefazoline) and Pool 2 (Panel B: 
amoxicilline, flucloxacillin, ceftazidime, ceftriaxone, ertapenem, daptomycin, 
rifampicin), constituted on the basis of the frequency of clinical requests for the 
respective antibiotics in the hospital routine antibiotic TDM program. 
Figure 2: Chromatographic profiles by UPLC-MS/MS of samples from patients receiving: 
imipenem/cilastatin (Panel A and B); cefepime (Panel C); meropenem (Panel D and 
E); daptomycin (Panel F); cefepime (Panel G, H, and I). The internal standards used 
for these antibiotics were their stable isotope-labelled analogues (see details in the 
text).
Figure 3: Isomers profiles and metabolites identification studies for imipenem and cefepime. 
Panel A.  Imipenem extended gradient for formamidinium E and Z isomers separation.
Panel B.   Cefepime and 7-epimer, in a patient sample.
9. TABLES INDEX AND LEGENDS
Table 1: LC-MS/MS method for quantification of plasma concentrations of antibiotics and their 
stable isotope-labelled analogues used as internal standards. Antibiotics are listed 
according to their inclusion in Pool 1 or Pool 2.
 
Table 2.  Left column. Evolution over time of antibiotic concentrations in plasma at room 
temperature (RT) and +4°C. Each time point represents the mean % difference from 
the initial nominal concentrations (analysed at T0) of the 4 QC levels (low (L), 
intermediate (I), medium (M) and high (H) at 0.5, 2.5, 7.5, and 75 µg/ml, respectively, 
with exception of piperacillin at 0.4. 4, 12, and 120 µg/ml, and rifampicin at 0.1, 0.5, 
1.5, and 15 µg/ml. 
Right column. Evolution over time at room temperature and at +4°C of antibiotic 
concentrations in plasma obtained from spiked citrated whole blood. Each time point 
represents the mean % difference from the initial nominal concentrations (analyzed 
at T0) for of the 4 QC levels.
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Table 1
ANALYTES Mean RT[min]







Imipenem 2.1* 300.20  98.00 37 57 1, 2
300.20  142.10 28 57 1, 2
Imipenem-D4 304.20  142.10 34 58 1
Cefepime 2.3 481.20  125.00 47 65 1, 2
481.20  396.2 11 65 1, 2
Cefepime-13CD3 485.30  125.00 53 71 1, 2
Tazobactam 2.4 301.38  94.10 22 104 1, 2
301.38  207.10 15 104 1, 2
Meropenem 2.6 384.20   68.10 35 59 2, 3
Meropenem-D6 390.70   68.10 35 77 2, 3
Cilastatin 2.9 359.30  97.00 22 67 2, 3
Cefazolin 3.1 384.20  68.10 35 59 2, 3
Piperacillin 3.8 518.20  114.00 46 93 3
518.20  115.10 48 93 3
518.20  143.10 29 93 3
Piperacillin-D5 523.30  116.20 53 94 3
523.30  148.30 21 94 3
Pool 2
366.10  114.10 25 61 1
366.10  134.10 30 61 1
366.10  349.30 7 61 1
Amoxicillin-D4 371.20  354.30 6 65 1
Ceftazidime 2.3 547.20  468.30 11 58 3
Ceftazidime-D6 553.20  474.80 13 69 3
Ceftriaxone 2.6 555.10  396.10 13 69 3
Ceftriaxone-13CD3 559.20  400.20 11 61 3
476.20    67.80 37 69 2
476.20  114.10 23 69 2
476.20  432.40 6 69 2
Ertapenem-D4 480.10  436.40 5 75 2
811.20  159.00 37 88 1, 2
811.20  313.20 28 88 1, 2
Daptomycin-D5 (major) 813.70  161.90 44 100 1, 2
454.10  114.10 36 74 1, 2
454.10  182.10 33 74 3
454.10  295.10 15 74 3
Flucloxacillin-13C4,15N 459.10  300.10 13 69 3
Rifampicin 4.7 823.40  791.70 16 80 3





* Imipenem exists as 2 formamidinium E and Z isomers in equilibrium that may be separated 
with extended gradient chromatographic conditions (see text and Figure 3A)
Polarity mode: Positive;  CE: collision energy ; RT :Retention Time;  MS acquisition time (min) = 5.0  
Q2 Collision gas pressure (mTorr) = 1.00 ; Polatity mode : Positive
Segment = 1 2 3 4
Duration (min) = 2.00 0.90 0.90 1.30
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Table 2
RT +4°C RT +4°C RT +4°C RT +4°C
0 1.8 1.8 0 0 0 0.8 0.8 0.0 0.0
1 -3.1 -3.0 -5.5 -2.1 1 2.5 2.1 0.1 0.6
2 -8.3 0.2 -8.7 -3.3 2 -0.6 -0.2 2.1 -1.4
4 -13.2 -2.7 -17.7 -7.6 4 6.2 -0.4 -4.1 2.9
8 -19.6 -1.3 -30.2 -12.9 8 -2.9 5.6 -3.2 -5.5
24 -60.9 -14.3 -63 -29.9 24 -9.7 1.4 -9.5 0.6
48 -88.2 -23.2 -84.8 -44.6 48 -24.5 -2.3 -14.1 -4.5
0 -1.4 -1.4 0 0 0 -1.2 -1.2 0.0 0.0
1 -0.7 0.3 -1.1 1.5 1 2.3 -7.1 3.8 -4.7
2 -5.5 -6.5 -2.4 0.4 2 -3.2 -1.5 3.4 -2.1
4 -8.1 -3.5 1.4 3 4 0.0 -1.6 -0.4 0.8
8 -11.0 -5.3 1.8 -0.7 8 -6.6 6.5 -6.4 -7.8
24 -35.2 -1.1 -7.2 0.5 24 -10.5 -0.7 -2.4 -2.2
48 -66.9 -12.2 -8.9 -2.7 48 -27.0 2.1 -10.8 -5.7
0 -2.1 -2.1 0 0 0 0.6 0.6 0.0 0.0
1 2.3 -6.0 -2.9 -0.2 1 0.5 3.9 -0.2 0.2
2 -5.0 -0.3 -1.5 -1.1 2 8.0 -6.7 3.9 -0.3
4 -5.7 -1.9 -4.4 -3.8 4 2.3 -4.2 1.4 0.2
8 -8.1 -3.9 -4.8 -5.2 8 2.4 0.0 -1.0 -4.1
24 -20.4 -9.1 -12.4 -2.9 24 -6.5 -1.6 2.5 3.0
48 -31.6 -8.7 -19.3 -5.9 48 -3.1 3.4 -1.3 -3.4
0 -5.2 -5.2 0 0 0 1.1 1.1 0.0 0.0
1 -3.0 -5.0 -2.4 -2.8 1 3.1 -2.8 3.7 -4.3
2 -6.7 -1.3 -6.2 -2.8 2 3.6 -0.4 1.4 -1.1
4 -6.1 -0.6 -8.5 -4.2 4 1.6 -2.9 -1.2 1.0
8 -5.4 -4.7 -13.8 -6.2 8 0.7 4.8 -3.5 -3.0
24 -24.5 -4.6 -33.6 -14.5 24 -10.1 0.7 -8.4 -2.1
48 -43.6 -9.0 -54.2 -20.6 48 -18.9 -3.4 -11.3 -6.9
0 2.3 2.3 0 0 0 -6.4 -6.4 0.0 0.0
1 8.0 -0.1 -3.6 -3 1 2.0 -5.3 -3.8 6.3
2 2.7 4.6 -2.7 -2 2 0.1 -7.7 -0.1 4.8
4 1.3 -3.3 -3.3 -2 4 1.8 -1.0 -6.3 6.5
8 6.9 0.9 -0.5 -1.9 8 0.9 -2.3 -0.3 3.3
24 0.9 6.1 -2 -0.7 24 2.2 -3.6 1.2 2.7
48 0.1 6.2 -1 -1.1 48 -2.3 -0.1 6.4 5.5
0 0.8 0.8 0 0 0 -0.1 -0.1 0.0 0.0
1 -0.2 -1.8 -1.2 -2.4 1 6.0 -1.5 -2.4 6.2
2 0.2 -3.2 -3 0.1 2 4.3 0.8 -1.5 -4.0
4 -7.7 -6.3 -3.5 -1.5 4 -1.1 0.3 -1.9 7.3
8 -8.8 -2.3 -4.3 -3.2 8 3.7 2.0 -6.7 -5.5
24 -38.2 -4.2 -8.2 -4.2 24 2.2 3.2 -3.4 2.1
48 -66.7 -6.6 -15.3 -3.2 48 -2.9 1.5 -14.3 -4.9
0 -3.7 -3.7 0.0 0.0
1 -2.2 -6.7 5.4 -1.1
2 -2.4 -5.4 5.2 -1.9
4 -5.7 -5.8 2.4 1.8
8 -6.2 -1.2 3.9 -0.6
24 -5.0 -3.7 -1.3 -0.2























Pool 1 Pool 2
Plasma Whole Blood
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Highlights
 Robust HPLC-MS/MS quantification of plasma levels of 12 daily-used antibiotics 
 Directly covering the entire clinically relevant ranges of concentrations
 Simple extraction, short turn-around time, stable isotope-labeled internal standards
 In vivo studies on isomers of imipenem and cefepime
 Suitable for adjusting antibiotics dosage for optimal efficacy and minimal toxicity 
